Patient perspective: Is intensive screening of women at high risk of breast cancer evidence-based medicine or <i>déjà vu</i>?

An important step in the right direction, the 2024 comparison of mortality with MRI versus no-MRI surveillance identified a significant benefit in BRCA1 mutation (hazard ratio (HR) = 0.20, 95% confidence interval (CI) = 0.10–0.43), but only a nonsignificant trend toward benefit in BRCA2 mutation (HR = 0.87, 95% CI = 0.10–17.25). 32 Its methodological limitations—a sample consisting almost entirely (97%) of White women, small number of mortality events, and no examination of earlier-age screening—could be addressed with rigorous population-level database analysis.

also in 5,406 other papers